[Benefits and risks of cyclooxygenase-2-selective inhibitor nonsteroidal antiinflammatory drugs]

Med Clin (Barc). 2002 Oct 5;119(11):429-34. doi: 10.1016/s0025-7753(02)73440-4.

[Article in Spanish]

Authors

Antonio Vallano¹, Roser Llop, Montserrat Bosch

Affiliation

¹ Fundació Institut Català de Farmacologia. Servei de Farmacologia Clínica. Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona. Barcelona. España.

PMID: 12381279
DOI: 10.1016/s0025-7753(02)73440-4

No abstract available

Publication types

Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
Cardiovascular Diseases / chemically induced
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / administration & dosage
Cyclooxygenase Inhibitors / adverse effects
Cyclooxygenase Inhibitors / pharmacology*
Humans
Isoenzymes / antagonists & inhibitors*
Kidney Diseases / chemically induced
Membrane Proteins
Prostaglandin-Endoperoxide Synthases
Skin Diseases / chemically induced

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Membrane Proteins
Cyclooxygenase 2
PTGS2 protein, human
Prostaglandin-Endoperoxide Synthases